Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Luo Website

Ji Luo, Ph.D.

Selected Publications

1)  Weng MT, Lee JH, Wei SC, Li Q, Shahamatdar S, Hsu D, Schetter AJ, Swatkoski S, Mannan P, Garfield S, Gucek M, Kim MK, Annunziata CM, Creighton CJ, Emanuele MJ, Harris CC, Sheu JC, Giaccone G, Luo J.
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells.
Proc. Natl. Acad. Sci. U.S.A. 109: E3659-67, 2012.
[Journal]
2)  Solimini NL, Xu Q, Mermel CH, Liang AC, Schlabach MR, Luo J, Burrows AE, Anselmo AN, Bredemeyer AL, Li MZ, Beroukhim R, Meyerson M, Elledge SJ.
Recurrent hemizygous deletions in cancers may optimize proliferative potential.
Science. 337: 104-9, 2012.
[Journal]
3)  Petrini I, Meltzer PS, Zucali PA, Luo J, Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, Roncalli M, Steinberg SM, Wang Y, Giaccone G.
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Cell Death Dis. 3: e351, 2012.
[Journal]
4)  Kessler JD, Kahle KT, Sun T, Meerbrey KL, Schlabach MR, Schmitt EM, Skinner SO, Xu Q, Li MZ, Hartman ZC, Rao M, Yu P, Dominguez-Vidana R, Liang AC, Solimini NL, Bernardi RJ, Yu B, Hsu T, Golding I, Luo J, Osborne CK, Creighton CJ, Hilsenbeck SG, Schiff R, Shaw CA, Elledge SJ, Westbrook TF.
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis.
Science. 335: 348-53, 2012.
[Journal]
5)  Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG.
Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis.
Proc. Natl. Acad. Sci. U.S.A. 109: 5322-7, 2012.
[Journal]
6)  Hu G, Luo J.
A primer on using pooled shRNA libraries for functional genomic screens.
Acta Biochim. Biophys. Sin. (Shanghai). 44: 103-12, 2012.
[Journal]
7)  Luo J.
Cancer's sweet tooth for serine.
Breast Cancer Res. 13: 317, 2011.
[Journal]
8)  Kaneko K, Ueki K, Takahashi N, Hashimoto S, Okamoto M, Awazawa M, Okazaki Y, Ohsugi M, Inabe K, Umehara T, Yoshida M, Kakei M, Kitamura T, Luo J, Kulkarni RN, Kahn CR, Kasai H, Cantley LC, Kadowaki T.
Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms.
Cell Metab. 12: 619-32, 2010.
[Journal]
9)  Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Cancer Res. 70: 5305-15, 2010.
[Journal]
10)  Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ.
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.
Cell. 137: 835-48, 2009.
[Journal]
11)  Hill JW, Xu Y, Preitner F, Fukuda M, Cho YR, Luo J, Balthasar N, Coppari R, Cantley LC, Kahn BB, Zhao JJ, Elmquist JK.
Phosphatidyl inositol 3-kinase signaling in hypothalamic proopiomelanocortin neurons contributes to the regulation of glucose homeostasis.
Endocrinology. 150: 4874-82, 2009.
[Journal]
12)  Luo J, Solimini NL, Elledge SJ.
Principles of cancer therapy: oncogene and non-oncogene addiction.
Cell. 136: 823-37, 2009.
[Journal]
13)  Schlabach MR, Luo J, Solimini NL, Hu G, Xu Q, Li MZ, Zhao Z, Smogorzewska A, Sowa ME, Ang XL, Westbrook TF, Liang AC, Chang K, Hackett JA, Harper JW, Hannon GJ, Elledge SJ.
Cancer proliferation gene discovery through functional genomics.
Science. 319: 620-4, 2008.
[Journal]
14)  Luo J, Elledge SJ.
Cancer: Deconstructing oncogenesis.
Nature. 453: 995-6, 2008.
[Journal]
15)  Solimini NL, Luo J, Elledge SJ.
Non-oncogene addiction and the stress phenotype of cancer cells.
Cell. 130: 986-8, 2007.
[Journal]
16)  Luo J, Sobkiw CL, Hirshman MF, Logsdon MN, Li TQ, Goodyear LJ, Cantley LC.
Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia.
Cell Metab. 3: 355-66, 2006.
[Journal]
17)  Taniguchi CM, Tran TT, Kondo T, Luo J, Ueki K, Cantley LC, Kahn CR.
Phosphoinositide 3-kinase regulatory subunit p85alpha suppresses insulin action via positive regulation of PTEN.
Proc. Natl. Acad. Sci. U.S.A. 103: 12093-7, 2006.
[Journal]
18)  Engelman JA, Luo J, Cantley LC.
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.
Nat. Rev. Genet. 7: 606-19, 2006.
[Journal]
19)  Yuan H, Luo J, Weissleder R, Cantley L, Josephson L.
Wortmannin-C20 conjugates generate wortmannin.
J. Med. Chem. 49: 740-7, 2006.
[Journal]
20)  Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePinho RA, Izumo S, Cantley LC.
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Mol. Cell. Biol. 25: 9491-502, 2005.
[Journal]
21)  Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC.
Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Proc. Natl. Acad. Sci. U.S.A. 102: 10238-43, 2005.
[Journal]
22)  Luo J, Cantley LC.
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Cell Cycle. 4: 1309-12, 2005.
[Journal]
23)  Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC.
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
J. Cell Biol. 170: 455-64, 2005.
[Journal]
24)  Luo J, Manning BD, Cantley LC.
Targeting the PI3K-Akt pathway in human cancer: rationale and promise.
Cancer Cell. 4: 257-62, 2003.
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 5/8/2013.